FRAX类风湿性关节炎患者10年骨折风险评估有无骨密度-我们是否在bDMARDs下治疗我们的患者?

IF 1.4 4区 医学 Q3 RHEUMATOLOGY
ARP Rheumatology Pub Date : 2023-01-01
Maria Seabra Rato, Filipe Oliveira Pinheiro, Salomé Garcia, Bruno Fernandes, Alexandra Bernardo, Rita Gaio, Lúcia Costa, Miguel Bernardes
{"title":"FRAX类风湿性关节炎患者10年骨折风险评估有无骨密度-我们是否在bDMARDs下治疗我们的患者?","authors":"Maria Seabra Rato,&nbsp;Filipe Oliveira Pinheiro,&nbsp;Salomé Garcia,&nbsp;Bruno Fernandes,&nbsp;Alexandra Bernardo,&nbsp;Rita Gaio,&nbsp;Lúcia Costa,&nbsp;Miguel Bernardes","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to identify the rheumatoid arthritis (RA) patients under biological therapy who have FRAX® scores classified as high fracture risk and to evaluate if they are receiving treatment for osteoporosis (OP). The authors also investigated the intra-individual agreement between FRAX® fracture risk calculated with and without bone mineral density (BMD).</p><p><strong>Methods: </strong>A single-center retrospective cohort study was performed in a total of 303 patients with RA under biologics. Demographic and clinical data were collected using Rheumatic Diseases Portuguese Register (Reuma.pt), complemented with data from the hospital clinical records. FRAX scores with and without BMD were calculated. The Kendall's Tau coefficient was used to assess the agreement between FRAX risk categories. Correlations were evaluated by the Spearman test. Comparisons of distributions from independent variables used the Mann-Whitney test.</p><p><strong>Results: </strong>When FRAX® score was calculated without BMD (n=303), 25% patients were categorized as high fracture risk. Among them, only 54% were receiving OP treatment. FRAX® assessment with BMD (n=231) identified 33% patients with high fracture risk, 52% in treatment for OP. Thirty patients (21%) previously classified as low fracture risk using FRAX® without BMD were recategorized as high risk (𝜏=0.570, p.</p>","PeriodicalId":29669,"journal":{"name":"ARP Rheumatology","volume":"2 1","pages":"47-52"},"PeriodicalIF":1.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density - are we treating our patients under bDMARDs?\",\"authors\":\"Maria Seabra Rato,&nbsp;Filipe Oliveira Pinheiro,&nbsp;Salomé Garcia,&nbsp;Bruno Fernandes,&nbsp;Alexandra Bernardo,&nbsp;Rita Gaio,&nbsp;Lúcia Costa,&nbsp;Miguel Bernardes\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to identify the rheumatoid arthritis (RA) patients under biological therapy who have FRAX® scores classified as high fracture risk and to evaluate if they are receiving treatment for osteoporosis (OP). The authors also investigated the intra-individual agreement between FRAX® fracture risk calculated with and without bone mineral density (BMD).</p><p><strong>Methods: </strong>A single-center retrospective cohort study was performed in a total of 303 patients with RA under biologics. Demographic and clinical data were collected using Rheumatic Diseases Portuguese Register (Reuma.pt), complemented with data from the hospital clinical records. FRAX scores with and without BMD were calculated. The Kendall's Tau coefficient was used to assess the agreement between FRAX risk categories. Correlations were evaluated by the Spearman test. Comparisons of distributions from independent variables used the Mann-Whitney test.</p><p><strong>Results: </strong>When FRAX® score was calculated without BMD (n=303), 25% patients were categorized as high fracture risk. Among them, only 54% were receiving OP treatment. FRAX® assessment with BMD (n=231) identified 33% patients with high fracture risk, 52% in treatment for OP. Thirty patients (21%) previously classified as low fracture risk using FRAX® without BMD were recategorized as high risk (𝜏=0.570, p.</p>\",\"PeriodicalId\":29669,\"journal\":{\"name\":\"ARP Rheumatology\",\"volume\":\"2 1\",\"pages\":\"47-52\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ARP Rheumatology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ARP Rheumatology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究旨在识别FRAX评分为高骨折风险的类风湿性关节炎(RA)患者,并评估他们是否正在接受骨质疏松症(OP)治疗。作者还研究了考虑和不考虑骨密度(BMD)的FRAX®骨折风险之间的个体内一致性。方法:采用单中心回顾性队列研究,共纳入303例接受生物制剂治疗的RA患者。使用葡萄牙风湿病登记册(Reuma.pt)收集人口统计和临床数据,并辅以医院临床记录的数据。计算有无骨密度的FRAX评分。Kendall's Tau系数用于评估FRAX风险类别之间的一致性。通过Spearman检验评估相关性。自变量分布的比较采用Mann-Whitney检验。结果:在没有骨密度的情况下计算FRAX评分时(n=303), 25%的患者被归为高骨折风险。其中,接受OP治疗的仅占54%。FRAX®骨密度评估(n=231)发现33%的患者骨折风险高,52%的患者骨折风险高。30例(21%)先前使用FRAX®无骨密度评估为低骨折风险的患者被重新划分为高风险(平均水平为0.570,p。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
FRAX 10-year fracture risk in rheumatoid arthritis assessed with and without bone mineral density - are we treating our patients under bDMARDs?

Objective: This study aimed to identify the rheumatoid arthritis (RA) patients under biological therapy who have FRAX® scores classified as high fracture risk and to evaluate if they are receiving treatment for osteoporosis (OP). The authors also investigated the intra-individual agreement between FRAX® fracture risk calculated with and without bone mineral density (BMD).

Methods: A single-center retrospective cohort study was performed in a total of 303 patients with RA under biologics. Demographic and clinical data were collected using Rheumatic Diseases Portuguese Register (Reuma.pt), complemented with data from the hospital clinical records. FRAX scores with and without BMD were calculated. The Kendall's Tau coefficient was used to assess the agreement between FRAX risk categories. Correlations were evaluated by the Spearman test. Comparisons of distributions from independent variables used the Mann-Whitney test.

Results: When FRAX® score was calculated without BMD (n=303), 25% patients were categorized as high fracture risk. Among them, only 54% were receiving OP treatment. FRAX® assessment with BMD (n=231) identified 33% patients with high fracture risk, 52% in treatment for OP. Thirty patients (21%) previously classified as low fracture risk using FRAX® without BMD were recategorized as high risk (𝜏=0.570, p.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信